ReviewJournal of neuro-oncology2026
MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions.
Review in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMGMT promoter methylation (MGMTpm) is a well-established molecular biomarker in neuro-oncology. We review current practices, challenges, and future directions for MGMTpm as a biomarker in central nervous system (CNS) tumors.
methodsThe literature on MGMT function, and MGMTpm clinical significance and testing in CNS tumors was reviewed.
resultsWe discuss the biological role of MGMT in DNA repair and the mechanisms by which MGMTpm leads to increased tumor sensitivity to alkylating agents. We summarize the clinical significance of MGMTpm in glioblastoma and its emerging relevance in other CNS tumors. Testing practices using methylation-specific PCR, pyrosequencing, and genome-wide methylation array-based approaches are discussed, along with challenges related to testing variability and "gray-zone" methylation, and emerging technologies such as nanopore sequencing.
conclusionsDespite ongoing technical and interpretative challenges, MGMTpm remains a robust and clinically valuable biomarker in neuro-oncology.
Indexed as
Identifiers
42867718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.